Songzi Li

机构：Renmin University of China

发表论文 49 篇 · 总被引 709 次 · h-index 12

代表论文

• Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma (2023 · JAMA Oncology · 被引 257)
• Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial (2022 · Journal of Thoracic Oncology · 被引 111)
• On the Law of Large Numbers for the Empirical Measure Process of Generalized Dyson Brownian Motion (2020 · Journal of Statistical Physics · 被引 18)
• Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study (2024 · Liver Cancer · 被引 9)
• The effects of tislelizumab treatment on the health‐related quality of life of patients with advanced non‐small cell lung cancer (2023 · Cancer Medicine · 被引 6)
• On the Renyi entropy power and the Gagliardo-Nirenberg-Sobolev inequality on Riemannian manifolds (2020 · arXiv (Cornell University) · 被引 6)